YTHDF2 and METTL3 have previously been reported as tumor suppressors in HCC, and as oncogenes in pancreatic cancer and acute myelocytic leukemia (Cui et al., 2017; Wang et al., 2017; Zhong et al., 2019). Here, METTL3 is linked to hepatocellular carcinoma.